2016
DOI: 10.1007/8904_2016_15
|View full text |Cite
|
Sign up to set email alerts
|

Inhaled Sargramostim Induces Resolution of Pulmonary Alveolar Proteinosis in Lysinuric Protein Intolerance

Abstract: Pulmonary alveolar proteinosis (PAP) is a potentially fatal complication of lysinuric protein intolerance (LPI), an inherited disorder of cationic amino acid transport. The patients often present with mild respiratory symptoms, which may rapidly progress to acute respiratory failure responding poorly to conventional treatment with steroids and bronchoalveolar lavations (BALs). The pathogenesis of PAP in LPI is still largely unclear. In previous studies, we have shown disturbances in the function and activity o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

2
8
0

Year Published

2017
2017
2024
2024

Publication Types

Select...
7
2

Relationship

1
8

Authors

Journals

citations
Cited by 14 publications
(12 citation statements)
references
References 20 publications
2
8
0
Order By: Relevance
“…Tanner also reported two patients diagnosed LPI with PAP who were treated with inhaled rGM‐CSF and achieved positive results 10. Our patient from case one inhaled rGM‐CSF for 1.5 years.…”
Section: Discussionsupporting
confidence: 54%
“…Tanner also reported two patients diagnosed LPI with PAP who were treated with inhaled rGM‐CSF and achieved positive results 10. Our patient from case one inhaled rGM‐CSF for 1.5 years.…”
Section: Discussionsupporting
confidence: 54%
“…Lung histology revealing collapsed alveoli with surfactant accumulations is the gold standard for diagnosis in experimental models of PAP. Slc7a7 −/− developed PAP in ~30% of the animals (i.e., 7 out of the 21 mice studied), a similar percentage as in LPI patients, which ranges from 10–60% in the different LPI cohorts [39,40]. Thus, PAS-positive material was found inside alveoli and was further confirmed by immunohistochemistry against surfactant protein B (SP-B, Figure 4).…”
Section: Resultsmentioning
confidence: 65%
“…Treatment of the immunological and bone marrow complications, including clinical hemophagocytic lymphohistiocytosis, is still experimental, but immunosuppressive drugs have had good responses in individual cases ( Bader-Meunier et al, 2000 ). Bronchoalveolar lavage and steroid therapy have been effective in some alveolar proteinosis cases ( Parto et al, 1994 ), and immunostimulating adjuvant therapy has been tried to mitigate the immunological abnormalities ( Tanner et al, 2017 ). The first in vivo model for LPI, a tamoxifen-inducible Slc7a7 KO mouse that recapitulates the human disease phenotype and responds to citrulline treatment, has emerged as a promising tool for designing future therapies, especially for the immunological complications of the disease ( Bodoy et al, 2019 ).…”
Section: The Fdhmentioning
confidence: 99%